These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 31152083)
1. Dancing with Deterrents: Understanding the Role of Abuse-Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain. Mitchell MT Oncologist; 2019 Dec; 24(12):1505-1509. PubMed ID: 31152083 [TBL] [Abstract][Full Text] [Related]
2. Abuse-deterrent opioids: an update on current approaches and considerations. Pergolizzi JV; Raffa RB; Taylor R; Vacalis S Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730 [TBL] [Abstract][Full Text] [Related]
3. Opioids with abuse-deterrent properties: A regulatory and technological overview. Haddox JD J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587 [TBL] [Abstract][Full Text] [Related]
4. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. Rauck RL Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739 [TBL] [Abstract][Full Text] [Related]
5. An evaluation method for developing abuse-deterrent opioid formulations with agonist and antagonist combinations using conditioned place preference. Zhang X; Kitaichi K; Mouri A; Zhou X; Nabeshima T; Yamada K; Nagai T Biochem Biophys Res Commun; 2023 Jan; 639():100-105. PubMed ID: 36476949 [TBL] [Abstract][Full Text] [Related]
6. Co-prescription of naloxone as a Universal Precautions model for patients on chronic opioid therapy-Observational study. Takeda MY; Katzman JG; Dole E; Bennett MH; Alchbli A; Duhigg D; Yonas H Subst Abus; 2016; 37(4):591-596. PubMed ID: 27093555 [TBL] [Abstract][Full Text] [Related]
7. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185 [TBL] [Abstract][Full Text] [Related]
8. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Gasior M; Bond M; Malamut R Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680 [TBL] [Abstract][Full Text] [Related]
9. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Webster L Pain Med; 2009 Jul; 10 Suppl 2():S124-33. PubMed ID: 19691683 [TBL] [Abstract][Full Text] [Related]
10. Use of risk mitigation practices by family nurse practitioners prescribing opioids for the management of chronic nonmalignant pain. Chaudhary S; Compton P Subst Abus; 2017; 38(1):95-104. PubMed ID: 27897471 [TBL] [Abstract][Full Text] [Related]
11. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Webster LR; Markman J; Cone EJ; Niebler G Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497 [TBL] [Abstract][Full Text] [Related]
12. Opioid abuse-deterrent strategies: role of clinicians in acute pain management. Webster LR; Brennan MJ; Kwong LM; Levandowski R; Gudin JA Postgrad Med; 2016 Jan; 128(1):76-84. PubMed ID: 26631936 [TBL] [Abstract][Full Text] [Related]
13. The prescription opioid conundrum: 21st century solutions to a millennia-long problem. Brennan MJ; Gudin JA Postgrad Med; 2020 Jan; 132(1):17-27. PubMed ID: 31591925 [TBL] [Abstract][Full Text] [Related]
14. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice. Lee YH; Brown DL; Chen HY Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148 [TBL] [Abstract][Full Text] [Related]
16. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Hale ME; Moe D; Bond M; Gasior M; Malamut R Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830 [TBL] [Abstract][Full Text] [Related]
17. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. Coffin PO; Behar E; Rowe C; Santos GM; Coffa D; Bald M; Vittinghoff E Ann Intern Med; 2016 Aug; 165(4):245-52. PubMed ID: 27366987 [TBL] [Abstract][Full Text] [Related]
18. Attitudes Toward Naloxone Prescribing in Clinical Settings: A Qualitative Study of Patients Prescribed High Dose Opioids for Chronic Non-Cancer Pain. Mueller SR; Koester S; Glanz JM; Gardner EM; Binswanger IA J Gen Intern Med; 2017 Mar; 32(3):277-283. PubMed ID: 27798775 [TBL] [Abstract][Full Text] [Related]
19. Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview. Butreddy A; Nyavanandi D; Narala S; Austin F; Bandari S Curr Drug Deliv; 2021; 18(1):4-18. PubMed ID: 32811398 [TBL] [Abstract][Full Text] [Related]
20. Distribution of naloxone for overdose prevention to chronic pain patients. Coe MA; Walsh SL Prev Med; 2015 Nov; 80():41-3. PubMed ID: 26024850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]